Table 1 Subject characteristics... | American Society of Hematology

Table 1

Subject characteristics

Characteristics	Data
Total, no.	17
No. men/no. women	9/8
Median age, y (range)	68 (49-88)
Rai stage, no.
0	5
1	5
2	3
3	3
4	1
Prior therapy, no.
None	11
Chlorambucil	2
Chlorambucil, rituximab	3
Cyclophosphamide, prednisone, rituximab	1
Median absolute lymphocyte count × 10⁹/L (range)	32.5 (1.8-224.4)
CD38⁻, no.	16
CD38⁺, no.	1
Interphase cytogenetics, FISH, no.
del 13q14	3
del 13q14, +12	1
del 13q14, ATM	1
p53	1
No abnormalities	2
Not available	9

Characteristics	Data
Total, no.	17
No. men/no. women	9/8
Median age, y (range)	68 (49-88)
Rai stage, no.
0	5
1	5
2	3
3	3
4	1
Prior therapy, no.
None	11
Chlorambucil	2
Chlorambucil, rituximab	3
Cyclophosphamide, prednisone, rituximab	1
Median absolute lymphocyte count × 10⁹/L (range)	32.5 (1.8-224.4)
CD38⁻, no.	16
CD38⁺, no.	1
Interphase cytogenetics, FISH, no.
del 13q14	3
del 13q14, +12	1
del 13q14, ATM	1
p53	1
No abnormalities	2
Not available	9